[go: up one dir, main page]

WO2019104070A1 - Lieur bifonctionnel photoclivable o-nitrobenzyle - Google Patents

Lieur bifonctionnel photoclivable o-nitrobenzyle Download PDF

Info

Publication number
WO2019104070A1
WO2019104070A1 PCT/US2018/062072 US2018062072W WO2019104070A1 WO 2019104070 A1 WO2019104070 A1 WO 2019104070A1 US 2018062072 W US2018062072 W US 2018062072W WO 2019104070 A1 WO2019104070 A1 WO 2019104070A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
region
alkenyl
haloc
probe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/062072
Other languages
English (en)
Inventor
Kim DAE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NS Wind Down Co Inc
Original Assignee
Nanostring Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanostring Technologies Inc filed Critical Nanostring Technologies Inc
Publication of WO2019104070A1 publication Critical patent/WO2019104070A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2433—Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1)
    • C07F9/2441—Compounds containing the structure N-P(=X)n-X-acyl, N-P(=X)n-X-heteroatom, N-P(=X)n-X-CN (X = O, S, Se; n = 0, 1) containing the structure N-P(=X)n-X-C(=X) (X = O, S, Se; n = 0, 1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Definitions

  • Photocleavable (“PC”) compounds play an important role as protecting groups in blocking functional groups present in nucleosides, nucleotides, sugars and amino acids, which are used for the synthesis of biomolecules, e.g. nucleic acids and their derivatives, proteins, peptides and carbohydrates. Such compounds have the advantage that deprotection of the protected functional group can be performed simply via light exposure. Therefore, photocleavable compounds provide the basis for the photolithography based spatially resolved synthesis of oligonucleotides or peptides on solid supports, such as microarrays. The use of photolabile compounds for the synthesis of microarrays is well known (Pease, et al. Proc. Natl. Acad. Sci. USA 91 (1994) 5022-5026), Hasan, et al. Tetrahedron 53 (1997) 4247- 4264).
  • Photocleavable compounds can also be used as photocleavable linker molecules to link different elements, such as two biomolecules, a biomolecule and a solid phase, a biomolecule and streptavidin.
  • two different oligonucleotides may be connected via the photocleavable compound in order to deliver a single stranded molecule to a biochemical or biological assay, which upon irradiation with light releases the two individual oligonucleotides which then may form a double stranded DNA and exhibit biological function.
  • the elements, which are photocleavably connected by the above mentioned compounds can be separated from each other simply due to light exposure. Such components are well known (Olejnik, et al. Proc. Natl.
  • R 1 is hydrogen, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2- 6 alkynyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynl are each independently optionally substituted with at least one substituent R 10 ;
  • R2 is O, NH, or N(C 1-6 alkyl);
  • R3 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with at least one substituent R 10 ;
  • each R 4 and R 7 are independently C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, wherein said C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynlene are each independently optionally substituted with at least one substituent R 10 ;
  • R 5 and R 9 are each independently cycloalkyl,
  • R 1 is C 1-6 alkyl, preferably C 1-3 alkyl such as methyl, ethyl, propyl or isopropyl;
  • R2 is NH or N(C 1-6 alkyl);
  • R3 is a 5- to 6-membered cycloalkyl, preferably cyclohexyl;
  • R 4 is C 1-6 alkylene, preferably C 1-3 alkylene such as methylene, ethylene, propylene, or isopropylene;
  • Rs is a 5- to 6- membered heterocyclyl comprising one nitrogen atom and 0 or 1 additional heteroatoms selected from N, O and S, wherein said heterocyclyl is optionally substituted with one or two R 10 ;
  • R 6 is O;
  • R 7 is C 1-6 alkylene, preferably C 1- 3alkylene such as methylene, ethylene, propylene, or isopropylene;
  • R 8 is O;
  • R 9 is a 5- to 6- membered heterocycl
  • R 3 is cyclohexyl
  • R 4 is methylene
  • R 5 is lH-pyrrole-2,5-dione
  • R 9 is pyrrolidine-2,5-dione, optionally substituted with SO 3 " .
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • R21 is hydrogen, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein said C 1-6 alkyl, C 2- ealkenyl, C 2-6 alkynl are each independently optionally substituted with at least one substituent R30;
  • R22 is O, NH, orN(C 1-6 alkyl);
  • R23 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with at least one substituent R30;
  • R24 is C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, wherein said C 1-6 alkylene, C 2- ealkenylene, C 2-6 alkynlene are each independently optionally substituted with at least one substituent R30;
  • R26 is a bond, O, NH or N(C 1-6 alkyl);
  • R27 is a bond, C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, wherein said C 1-6 alkylene, C 2- ealkenylene, C 2-6 alkynlene are each independently optionally substituted with at least one substituent R30;
  • R26 is a bond, then R27 is also a bond
  • R28 is OP(OR 1 XNR31R32);
  • each R30 is independently hydrogen, halogen, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, haloC 1- 6 alkyl, halo C 2-6 alkenyl, haloC 2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -
  • R31, R32, and R33 which may be the same or different, are each independently hydrogen, -C 1- 6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, haloC 1-6 alkyl, haloC 2-6 alkenyl, haloC 2-6 alkynyl, C 1- 6 alkyloxyC 1-6 alkyl-, cycloalkyl, heterocyclyl, aryl, heteroaryl, or a protecting group.
  • the present disclosure also provides a probe comprising a first region comprising a first target-specific sequence and a second region which does not overlap with the first region; second region comprising a first label attachment region which is hybridized to a first DNA or RNA molecule, wherein the first DNA or RNA molecule is attached to one or more label monomers that emit light constituting a first signal; and a second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to a second DNA or RNA molecule, wherein the second DNA or RNA molecule is attached to one or more label monomers that emit light constituting a second signal, and wherein the label attachment regions do not overlap; and a compound of Formula I disclosed herein linking the first region and the second region.
  • the present disclosure also provides a composition
  • a composition comprising a first probe and a second probe, the first probe comprising a first region comprising a first target-specific sequence; a second region which does not overlap with the first region, the second region comprising a first label attachment region which is hybridized to a first DNA or RNA molecule, wherein the first DNA or RNA molecule is attached to one or more label monomers that emit light constituting a first signal; and a second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to a second DNA or RNA molecule, wherein the second DNA or RNA molecule is attached to one or more label monomers that emit light constituting a second signal, and wherein the label attachment regions do not overlap; and a compound of Formula I disclosed herein linking the first region and the second region; the second probe comprising a first region comprising a first target-specific sequence, wherein the target-specific sequence of the first probe and the target-specific sequence of the second probe are different; and a second
  • the present disclosure also provides methods of detecting nucleic acid molecules utilizing the probes and compositions disclosed herein.
  • Figure 1 is a schematic illustration of an exemplary probe comprising a linker of the present disclosure.
  • Figure 2 is a schematic illustration of an exemplary nanreporter probe complex comprising a linker of the present disclosure.
  • Figure 3 is a schematic illustration of an exemplary sequencing method using a probe comprising a linker modification of the present disclosure.
  • Figure 4 is a schematic illustration of an exemplary probe complex and the locations within the complex that may comprise linkers of the present disclosure.
  • R 1 is hydrogen, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2- «alkynyl, wherein said C 1-6 alkyl, C 2- ealkenyl, C 2-6 alkynl are each independently optionally substituted with at least one substituent R 10 ;
  • R2 is O, NH, orN(C 1-6 alkyl);
  • R3 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with at least one substituent R 10 ;
  • each R» and R 7 are independently C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, wherein said C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynlene are each independently optionally substituted with at least one substituent R 10 ;
  • R5 and R 9 are each independently cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with at least one substituent R 10 ;
  • R 6 is O, NH or N(C 1-6 alkyl);
  • R 8 is O, NH, orN(C 1-6 alkyl);
  • R11, R12, and R13 which may be the same or different, are each independently hydrogen, -C 1- 6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, haloC 1-6 alkyl, haloC 2-6 alkenyl, haloC 2-6 alkynyl, C 1- 6 alkyloxyC 1-6 alkyl-, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
  • R 1 is C 1-6 alkyl, preferably C 1- 3alkyl such as methyl, ethyl, propyl or isopropyl;
  • R2 is NH orN(C 1-6 alkyl);
  • R3 is a 5- to 6-membered cycloalkyl, preferably cyclohexyl;
  • R 4 is C 1-6 alkylene, preferably C 1- 3alkylene such as methylene, ethylene, propylene, or isopropylene;
  • R5 is a 5- to 6- membered heterocyclyl comprising one nitrogen atom and 0 or 1 additional heteroatoms selected from N, O and S, wherein said heterocyclyl is optionally substituted with one or two R 10 ;
  • R 6 is O
  • R 7 is C 1-6 alkylene, preferably C 1- 3alkylene such as methylene, ethylene, propylene, or isopropylene;
  • R 8 is O
  • R 9 is a 5- to 6- membered heterocyclyl comprising one nitrogen atom and 0 or 1 additional heteroatoms selected from N, O and S, wherein said heterocyclyl is optionally substituted with one or two R 10 ;
  • each R 10 is independently halogen, C 1-6 alkyl, haloC 1-6 alkyl, oxo, -SO2H, or -SO 3 H.
  • R3 is cyclohexyl and R» is methylene.
  • Rs is lH-pyrrole-2,5-dione.
  • R 9 is pyrrolidine-2,5-dione, optionally substituted with SO 3 H.
  • R21 is hydrogen, halogen, C 1-6 alkyl, C 2- «alkenyl, C 2-6 alkynyl, wherein said C 1-6 alkyl, C 2- 6 alkenyl, C 2-6 alkynl are each independently optionally substituted with at least one substituent R30;
  • R22 is O, NH, orN(C 1-6 alkyl);
  • R23 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each optionally substituted with at least one substituent R30;
  • R24 is C 1-6 alkylene, C 2- «alkenylene, C 2-6 alkynylene, wherein said C 1-6 alkylene, C 2- 6 alkenylene, C 2-6 alkynlene are each independently optionally substituted with at least one substituent R30;
  • R26 is a bond, O, NH or N(C ⁇ alkyl);
  • R27 is a bond, C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, wherein said C 1-6 alkylene, C 2- 6 alkenylene, C 2-6 alkynlene are each independently optionally substituted with at least one substituent R30;
  • R26 is a bond, then R27 is also a bond
  • R28 is OP(OR 1 XNR31R32); each R30 is independently hydrogen, halogen, -C 1-6 alkyl, -C 2- «alkenyl, -C 2-6 alkynyl, haloC 1- 6 alkyl, haloC 2-6 alkenyl, haloC 2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -
  • R31, R32, and R33 which may be the same or different, are each independently hydrogen, -C 1- 6 alkyl, -C 2- «alkenyl, -C 2-6 alkynyl, haloC 1-6 alkyl, haloC 2-6 alkenyl, haloC 2-6 alkynyl, C 1- 6 alkyloxyC 1-6 alkyl-, cycloalkyl, heterocyclyl, aryl, heteroaryl, or a protecting group.
  • R21 is C 1-6 alkyl, preferably C 1- 3alkyl such as methyl, ethyl, propyl or isopropyl;
  • R22 is NH or N(C 1-6 alkyl);
  • R23 is a 5- to 6-membered cycloalkyl, preferably cyclohexyl
  • R24 is C 1-6 alkylene, preferably C 1-3 alkylene such as methylene, ethylene, propylene, or isopropylene, substituted with -OR31;
  • R26 is O
  • R27 is C 1-6 alkylene, preferably C 1- 3alkylene such as methylene, ethylene, propylene, or isopropylene;
  • R28 is a phosphoramidite moiety
  • R31 is hydrogen or a hydroxyl protecting group, such as DMT.
  • R23 is cyclohexyl and R24 is methylene substituted with -OH, optionally protected by a protecting group.
  • PG is hydrogen or a protecting group, and wherein n is 1-3, or a stereoisomer or salt thereof.
  • PG is hydrogen or a protecting group, or a stereoisomer or salt thereof.
  • PG is hydrogen or a protecting group, or a stereoisomer or salt thereof.
  • alkyl herein refers to a hydrocarbon group selected from linear and branched saturated hydrocarbon groups comprising from 1 to 18, such as from 1 to 12, further such as from 1 to 10, more further such as from 1 to 8, or from 1 to 6, or from 1 to 4, carbon atoms.
  • alkyl groups comprising from 1 to 6 carbon atoms include, but not limited to methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1 -butyl or n-butyl ("n-Bu”), 2-methyl- 1-propyl or isobutyl ("i-Bu”), 1- methylpropyl or s-butyl ("s-Bu”), 1,1 -dimethyl ethyl or t-butyl (“t-Bu”), 1-pentyl, 2-pentyl, 3- pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3 -methyl- 1 -butyl, 2-methyl- 1 -butyl, 1-hexyl, 2- hexyl, 3-hexyl, 2-methyl -2-pentyl, 3-methyl-2-pentyl,
  • halogen herein refers to fluoro (F), chloro (CI), bromo (Br) and iodo (I).
  • haloalkyl refers to an alkyl group in which one or more hydrogen is/are replaced by one or more halogen atoms such as fluoro (F), chloro (CI), bromo (Br), and iodo (I).
  • haloalkyl include haloC 1-6 alkyl, haloC 1-6 alkyl or halo C 1- 4alkyl, but not limited to -CF 3 , -CH2CI, -CH2 CF3, -CCI2, CF 3 , and the like.
  • alkenyl group examples include, but not limited to ethenyl or vinyl, prop-l-enyl, prop-2- enyl, 2-methylprop-l-enyl, but-l-enyl, but-2-enyl, but-3-enyl, buta-l,3-dienyl, 2-methylbuta- 1,3-dienyl, hex-l-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-l,3-dienyl groups.
  • alkenylene groups present in bivalent form, also referred to herein as "alkenylene" groups, with exemplary groups including ethenylene, vinylene, and the like.
  • alkynyl refers to a hydrocarbon group selected from linear and branched hydrocarbon group, comprising at least one C ⁇ C triple bond and from 2 to 18, such as 2 to 8, further such as from 2 to 6, carbon atoms.
  • alkynyl group e.g., C 2- 6 alkynyl
  • examples of the alkynyl group include, but not limited to ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2- butynyl, and 3-butynyl groups.
  • alkynylene groups, with exemplary groups including ethynylene, 1-propynylene, and the like.
  • alkyloxy refers to an alkyl group as defined above bonded to oxygen, represented by -Oalkyl.
  • alkyloxy e.g., C 1-6 alkyloxy or CM alkyloxy includes, but not limited to, methoxy, ethoxy, isopropoxy, propoxy, n-butoxy, tert-butoxy, pentoxy and hexoxy and the like.
  • cycloalkyl refers to a hydrocarbon group selected from saturated and partially unsaturated cyclic hydrocarbon groups, comprising monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups.
  • the cycloalkyl group may comprise from 3 to 12, such as from 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5, or 3 to 4 carbon atoms.
  • the cycloalkyl group may be selected from monocyclic group comprising from 3 to 12, such as from 3 to 10, further such as 3 to 8, 3 to 6 carbon atoms.
  • Examples of the monocyclic cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, l-cyclopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups.
  • Examples of the saturated monocyclic cycloalkyl group include, but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
  • the cycloalkyl is a monocyclic ring comprising 3 to 6 carbon atoms (abbreviated as C3-6 cycloalkyl), including but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • bicyclic cycloalkyl groups include those having from 7 to 12 ring atoms arranged as a bicyclic ring selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems, or as a bridged bicyclic ring selected from
  • bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane examples include those arranged as a bicyclic ring selected from [5,6]
  • f and [6,6] ring systems such as ⁇ f ⁇ - ⁇ and wherein the wavy lines indicate the points of attachment.
  • the ring may be saturated or have at least one double bond (i.e.
  • aryl used alone or in combination with other terms refers to a group selected from: 5- and 6-membered carbocyclic aromatic rings, e.g., phenyl; bicyclic ring systems such as 7 to 12 membered bicyclic ring systems, wherein at least one ring is carbocyclic and aromatic, e.g., naphthyl and indanyl; and, tricyclic ring systems such as 10 to 15 membered tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, e.g., fluorenyl.
  • aromatic hydrocarbon ring and aryl are used interchangeable throughout the disclosure herein.
  • a monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring-forming carbon atoms (i.e., C5-10 aryl).
  • Examples of a monocyclic or bicyclic aromatic hydrocarbon ring includes, but not limited to, phenyl, naphth-l-yl, naphth-2-yl, anthracenyl, phenanthrenyl, and the like.
  • the aromatic hydrocarbon ring is a naphthalene ring (naphth-l-yl or naphth-2-yl) or phenyl ring.
  • the aromatic hydrocarbon ring is a phenyl ring.
  • heteroaryl refers to a group selected from: 5-, 6- or 7-membered aromatic, monocyclic rings comprising at least one heteroatom, for example, from 1 to 4, or, in some aspects, from 1 to 3, in some aspects, from 1 to 2, heteroatoms, selected from nitrogen (N), sulfur (S) and oxygen (O), with the remaining ring atoms being carbon; 8- to 12-membered bicyclic rings comprising at least one heteroatom, for example, from 1 to 4, or, in some aspects, from 1 to 3, or, in other aspects, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and 11- to 14-membered tricyclic rings comprising at least one heteroatom, for example, from 1 to 4, or in some aspects, from 1 to 3, or, in other aspects, 1 or 2, heteroatoms, selected from N, O, and S, with the
  • heteroaryl is 5- to 6-membered heteroaryl comprising one nitrogen atom and 0 or 1 additional heteroatom selected from N, O and S, including but not limited to pyridinyl, isoxazolyl, and oxazolyl.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some aspects, the total number of S and O atoms in the heteroaryl group is not more than 2. In some aspects, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. The nitrogen atoms in the ring(s) of the heteroaryl group can be oxidized to form N-oxides.
  • a monocyclic or bicyclic aromatic heterocyclic ring has 5-, 6-, 7-, 8-, 9- or 10-ring forming members with 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen (N), sulfur (S) and oxygen (O) and the remaining ring members being carbon.
  • the monocyclic or bicyclic aromatic heterocyclic ring is a monocyclic or bicyclic ring comprising 1 or 2 heteroatom ring members independently selected from nitrogen (N), sulfur (S) and oxygen (O).
  • the monocyclic or bicyclic aromatic heterocyclic ring is a 5- to 6- membered heteroaryl ring, which is monocyclic and which has 1 or 2 heteroatom ring members independently selected from nitrogen (N), sulfur (S) and oxygen (O).
  • the monocyclic or bicyclic aromatic heterocyclic ring is a 8- to 10-membered heteroaryl ring, which is bicyclic and which has 1 or 2 heteroatom ring members
  • heteroaryl group or the monocyclic or bicyclic aromatic heterocyclic ring include, but are not limited to, (as numbered from the linkage position assigned priority 1) pyridyl (such as 2-pyridyl, 3-pyridyl, or 4-pyridyl), cinnolinyl, pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl (such as 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, or 1,3,4-thiadiazolyl), tetrazolyl, thienyl (such as thien-2-yl, thien-3-yl), triazinyl, benzothienyl, furyl or furanyl, benzofuryl, benzo
  • benzothiophenyl benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, benzothiazolyl (such as benzo[d]thiazol-6-yl), indazolyl (such as lH-indazol- 5-yl) and 5,6,7,8-tetrahydroisoquinoline.
  • heterocyclic or “heterocycle” or “heterocyclyl” herein refers to a ring selected from 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11- or 12-membered monocyclic, bicyclic and tricyclic, saturated and partially unsaturated rings comprising at least one carbon atoms in addition to at least one heteroatom, such as from 1-4 heteroatoms, further such as from 1-3, or further such as 1 or 2 heteroatoms, selected from nitrogen (N), sulfur (S) and oxygen (O).
  • a heterocyclyl group is 4-, 5-, 6- or 7-membered monocyclic ring with at least one heteroatom selected from N, O and S.
  • Heterocycle herein also refers to a 5- to 7- membered heterocyclic ring comprising at least one heteroatom selected from N, O, and S fused with 5-, 6-, and /or 7-membered cycloalkyl, carbocyclic aromatic or heteroaromatic ring, provided that the point of attachment is at the heterocyclic ring when the heterocyclic ring is fused with a carbocyclic aromatic or a heteroaromatic ring, and that the point of attachment can be at the cycloalkyl or heterocyclic ring when the heterocyclic ring is fused with cycloalkyl.
  • Heterocycle herein also refers to an aliphatic spirocyclic ring comprising at least one heteroatom selected from N, O, and S, provided that the point of attachment is at the heterocyclic ring.
  • the rings may be saturated or have at least one double bond (i.e.
  • heterocycle may be substituted with oxo.
  • the point of the attachment may be carbon or heteroatom in the heterocyclic ring.
  • a heterocycle is not a heteroaryl as defined herein.
  • heterocyclyl is 5- to 6-membered heterocyclyl comprising one nitrogen atom and 0 or 1 additional heteroatom selected from N, O and S, including but not limited to pyrrolyl, dihydropyridine, morpholino, morpholinyl and tetraphydropyranyl.
  • the substituted 5- to 6-membered heterocyclyl comprising one nitrogen atom and 0 or 1 additional heteroatom selected from N, O and S includes, but not limited, ⁇ -butyrolactam, ⁇ -valerolactam, piperazin-2-one, pyrrolidine-2,5- dione, pyridin-2(lH)-one, l,5-dihydro-2H-pyrrol-2-one, pyrrolidin-2-one or lH-pyrrole-2,5- dione group.
  • heterocycle examples include, but not limited to, (as numbered from the linkage position assigned priority 1) 1-pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3- pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2,5-piperazinyl, pyranyl, morpholinyl, morpholino, 2-morpholinyl, 3-morpholinyl, oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl,
  • tetrahydrothiopyranyl 1 -pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H- pyranyl, 1,4-dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrazolidinyl, imidazolinyl, pyrimidinonyl, l,l-dioxo-thiomo ⁇ holinyl, 3- azabicyco[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl and azabicyclo[2.2.2]hexanyl.
  • a substituted heterocycle also includes a ring system substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1 -oxo- 1 -thiomorpholinyl and 1,1-dioxo-l- thiomorpholinyl.
  • oxo moieties such as piperidinyl N-oxide, morpholinyl-N-oxide, 1 -oxo- 1 -thiomorpholinyl and 1,1-dioxo-l- thiomorpholinyl.
  • protecting group refers to a group used to mask a moiety which would be reactive or labile under conditions used in a chemical reaction. In some cases, the appropriate protecting group is subject to cleavage after the chemical reaction.
  • exemplary groups include those applicable to oligonucleotide synthesis, such as dimethoxytrityl (DMT), methoxytrityl (MMT), and others known to those of skill in the art.
  • Enantiomers refer to two stereoisomers of a compound which are non- superimposable mirror images of one another. Where the compounds disclosed herein possess two or more asymmetric centers, they may additionally exist as diastereomers.
  • Enantiomers and diastereomers fall within the broader class of stereoisomers. All such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers are intended to be included. All stereoisomers of the compounds disclosed herein and /or pharmaceutically acceptable salts thereof are intended to be included. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included.
  • the term "substantially pure” as used herein means that the target stereoisomer contains no more than 35%, such as no more than 30%, further such as no more than 25%, even further such as no more than 20%, by weight of any other stereoisomer(s). In some aspects, the term “substantially pure” means that the target stereoisomer contains no more than 10%, for example, no more than 5%, such as no more than 1%, by weight of any other stereoisomer(s).
  • reaction products may be advantageous to separate reaction products from one another and /or from starting materials.
  • the desired products of each step or series of steps is separated and /or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art.
  • separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography.
  • Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed (“SMB”) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.
  • SMB simulated moving bed
  • One skilled in the art will apply techniques most likely to achieve the desired separation.
  • “Diastereomers” refers to stereoisomers of a compound with two or more chiral centers but which are not mirror images of one another.
  • Di aster eom eric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and /or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • Enantiomers can also be separated by use of a chiral HPLC column.
  • a single stereoisomer e.g., a substantially pure enantiomer
  • a method such as formation of diastereomers using optically active resolving agents (Eliel, E. mid Wilen, S. Stereochemistry of Organic
  • Racemic mixtures of chiral compounds of the disclosure can be separated and isolated by any suitable method, including: (1) formation of ionic,
  • the reaction for preparing compounds described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials, the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's boiling temperature. A given reaction can be carried out in one solvent or mixture of solvents. [0064] The selection of appropriate protecting group, can be readily determined by one skilled in the art.
  • Reactions can be monitored according to any suitable method known in the art, such as NMR, UV, HPLC, LC-MS and TLC.
  • Compounds can be purified by a variety of methods, including HPLC and normal phase silica chromatography.
  • 6-Hydroxy-2-nitroacetophenone (2.56 g, 14.1 mmol), ethyl -4-bromobutyrate (2.72 g, 13.9 mmol), and potassium carbonate (3.89 g, 28.1 mmol) were added to DMF (15 mL) and stirred overnight at 75 °C.
  • the solution was poured into water (300 mL), stirred for 1 hour at room temperature, and for 2 hours at 5 °C.
  • the resultant precipitate was filtered and washed with water. The product was dried and collected as a yellow solid.
  • the present disclosure also provides probes comprising two regions, a first region comprising a target-specific sequence, and a second region that does not bind to the target containing at least one label attachment region, wherein the interface between the first region and the second region comprises a linker of the present disclosure.
  • the first region and the second region can be linked by a compound of Formula I.
  • the probes of the present disclosure can be referred to as "nanoreporter probes".
  • the first region and the second region do not overlap.
  • the at least one label attachment region is capable of hybridizing to at least one DNA or RNA molecule, wherein the DNA or RNA molecule is labeled or attached to one or more label monomers that emit a signal that contributes to a code for detecting and identifying the target molecule.
  • This probe is referred to herein as a reporter probe or a nanoreporter, these terms are used
  • Nanoreporters are preferably synthetic, i.e., non-naturally-occurring, nucleic acid molecules.
  • the first region with the target-specific sequence is also referred to herein as the target binding domain.
  • the second region containing at least one label attachment region is also referred to herein as the barcode domain.
  • the target binding domain of a nanoreporter probe can comprise one more nucleotide sequences that can be hybridized to a target nucleic acid that is to be detected or sequenced, or to a barcode domain of another nanoreporter probe.
  • the target binding domain can comprise a series of nucleotides (e.g. is a
  • the target binding domain can comprise DNA, RNA, or a combination thereof In the case when the target binding domain is a polynucleotide, the target binding domain binds to a target nucleic acid by hybridizing to a portion of the target nucleic acid that is complementary to the target binding domain of the sequencing probe.
  • the target binding domain can be any amount or number of nucleotides in length.
  • the target binding domain can comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least 10, at least 11, at least 12, at least 13, at least 14, at least IS, at least 16, at least 17, at least 18, at least 19, or at least 20 nucleotides.
  • the target binding domain can comprise at least one natural base.
  • the target binding domain can comprise no natural bases.
  • the target binding domain can comprise at least one modified nucleotide or nucleic acid analog.
  • the target binding domain can comprise no modified nucleotides or nucleic acid analogs.
  • the target binding domain can comprise at least one universal base.
  • the target binding domain can comprise no universal bases.
  • the target binding domain can comprise at least one degenerate base.
  • the target binding domain can comprise no degenerate bases.
  • the target domain can comprise any combination natural bases (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more natural bases), modified nucleotides or nucleic acid analogs (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modified or analog nucleotides), universal bases (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more universal bases), or degenerate bases (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more degenerative bases).
  • natural bases, modified nucleotides or nucleic acid analogs, universal bases and degenerate bases of a particular target binding domain can be arranged in any order.
  • modified nucleotides or “nucleic acid analogues” include, but are not limited to, locked nucleic acids (LNA), bridged nucleic acids (BNA), propyne-modified nucleic acids, zip nucleic acids (ZNA ® ), isoguanine and isocytosine.
  • the target binding domain can include zero to six (e.g. 0, 1, 2, 3, 4, 5 or 6) modified nucleotides or nucleic acid analogues.
  • the modified nucleotides or nucleic acid analogues are locked nucleic acids (LNAs).
  • locked nucleic acids includes, but is not limited to, a modified RNA nucleotide in which the ribose moiety comprises a methylene bridge connecting the 2' oxygen and the 4' carbon. This methylene bridge locks the ribose in the 3'- endo confirmation, also known as the north confirmation, that is found in A-form RNA duplexes.
  • inaccessible RNA can be used interchangeably with LNA.
  • bridged nucleic acids (BNA) as used herein includes, but is not limited to, modified RNA molecules that comprise a five-membered or six-membered bridged structure with a fixed 3'- endo confirmation, also known as the north confirmation.
  • the bridged structure connects the 2' oxygen of the ribose to the 4' carbon of the ribose.
  • Various different bridge structures are possible containing carbon, nitrogen, and hydrogen atoms.
  • the term "propyne-modified nucleic acids” as used herein includes, but is not limited to, pyrimidines, namely cytosine and thymine/uracil, that comprise a propyne modification at the C5 position of the nucleic acid base.
  • the term "zip nucleic acids (ZNA ® )” as used herein includes, but is not limited to, oligonucleotides that are conjugated with cationic spermine moieties.
  • universal base includes, but is not limited to, a nucleotide base does not follow Watson-Crick base pair rules but rather can bind to any of the four canonical bases (A, T/U, C, G) located on the target nucleic acid.
  • degenerate base includes, but is not limited to, a nucleotide base that does not follow Watson- Crick base pair rules but rather can bind to at least two of the four canonical bases A, T/U, C, G), but not all four.
  • a degenerate base can also be termed a Wobble base; these terms are used interchangeably herein.
  • the target binding domain can also comprise a minor-groove binder moiety.
  • a minor-groove binder moiety is a chemical modification of an oligonucleotide that adds a chemical moiety that can bind to the minor groove of the target nucleotide to which the oligonucleotide is hybridized.
  • the inclusion of a minor-groove binder moiety increases the affinity of a target binding domain for a target nucleic acid, increasing the melting temperature of the target binding domain-target nucleic acid duplex. The higher binding affinity can allow for use of a smaller target binding domain.
  • the target binding domain can also comprise one or more twisted intercalating nucleic acids (ITNAs).
  • TINA is a nucleic acid molecule that stabilizes the formation of Hoogsteen triplex DNA from double-stranded oligonucleotides and triplex-forming oligonucleotides. TINAs can be used to stabilize a double-stranded oligonucleotides, thereby improving the specificity and sensitivity of an oligonucleotide probe to a target nucleic acid.
  • the target binding domain can also comprise nucleic acid molecules comprising a 2'- O-methyl-modified base.
  • a 2'-0-methyl-modified base is a nucleoside modification of RNA in which a methyl group is added to the 2' hydroxyl group of the ribose to produce a 2' methoxy group.
  • a 2'-0-methyl-modified base offers superior protection against base hydrolysis and digestion by nucleases. Without being bound by theory, the addition of a 2'- O-m ethyl -modified base also increases the melting temperature of a nucleic acid duplex.
  • the target binding domain can also comprise a covalently linked stilbene
  • a stilbene modification can increase the stability of a nucleic acid duplex.
  • Table 1 provides several other configurations of target binding domains of the present disclosure.
  • the target binding domain can comprise an antibody.
  • antibody herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bi specific antibodies), and antibody fragments so long as they exhibit the desired antigen- binding activity.
  • An antibody that binds to a target refers to an antibody that is capable of binding the target with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting the target.
  • the extent of binding of an anti-target antibody to an unrelated, non-target protein is less than about 10% of the binding of the antibody to target as measured, e.g., by a radioimmunoassay (RIA) or biacore assay.
  • an antibody that binds to a target has a dissociation constant (Kd) of ⁇ 1 uM, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g. 10 8 M or less, e.g. from 10* M to 10 13 M, e.g., from 10 9 M to 10 13 M).
  • Kd dissociation constant
  • an anti-target antibody binds to an epitope of a target that is conserved among different species.
  • the target binding domain can comprise an antibody fragment.
  • antibody fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
  • antibody fragments include but are not limited to Fv, Fab, Fab 1 , Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.
  • the barcode domain of a nanoreporter probe comprises a unique, designed nanoreporter.
  • the nanoreporter comprises one or more, e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more, unique, designed nucleotide sequences that can be hybridized to other nanoreporter probes or to molecules bound by or comprising at least one detectable label.
  • the nucleotide sequences can comprise at least 4, or at least 5, at least 6, or at least 7, or at least 8, or at least 9, or at least 10, or at least 11, or at least 12, or at least 13, or at least 14, or at least 15, or at least 16 or at least, 17 , or at least 18, or at least 19, or at least 20, or at least 21, or at least 22, or at least 23, or at least 24, or at least 25, or at least 26, or at least 27, or at least 28, or at least 29, or at least 30 nucleotides.
  • the nucleotide sequences of the nanoreporter of a single nanoreporter probe can be designed such that: (a) the nucleotide sequences specifically correspond to the nucleotide sequences present in the target binding domain of that same nanoreporter probe; and (b) the nucleotide sequences can be hybridized to one or more specific, predetermined nanoreporter probes or to one or more molecules bound by or comprising a specific, predetermined label.
  • the nanoreporter probe when the nanoreporter is hybridized to one or more molecules bound by or comprising a predetermined detectable label, the nanoreporter probe will emit a detectable single that distinguishes it from other nanoreporter probes and identifies the sequence present in the target binding domain of that nanoreporter probe.
  • the barcode domain can comprise at least one natural base.
  • the barcode domain can comprise no natural bases.
  • the barcode domain can comprise at least one modified nucleotide or nucleic acid analog.
  • the barcode domain can comprise no modified nucleotides or nucleic acid analogs.
  • the barcode domain can comprise at least one universal base.
  • the barcode domain can comprise no universal bases.
  • the barcode domain can comprise at least one degenerate base.
  • the barcode domain can comprise no degenerate bases.
  • the target domain can comprise any combination natural bases (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more natural bases), modified nucleotides or nucleic acid analogs (e.g.
  • nucleotides 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modified or analog nucleotides
  • universal bases e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more universal bases
  • degenerate bases e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more degenerative bases.
  • the natural bases, modified nucleotides or nucleic acid analogs, universal bases and degenerate bases of a particular barcode domain can be arranged in any order.
  • a nanoreporter can comprise at least one detectable label.
  • a nanoreporter can comprise at least 2 , at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100 detectable labels.
  • a nanoreporter can comprise a plurality of a first detectable label.
  • a nanoreporter can comprise a plurality of a first detectable label and a plurality of an at least second detectable label.
  • a nanoreporter can comprise a plurality of a first detectable label and a plurality of an at least second detectable label, wherein the number of first detectable labels is equal to the number of detectable labels.
  • a nanoreporter can comprise a plurality of a first detectable label and a plurality of an at least second detectable label, wherein the number of first detectable labels is not equal to the number of detectable labels.
  • detectable moiety A detectable moiety, label or reporter can be bound to a nanoreporter probe in a variety of ways, including the direct or indirect attachment of a detectable moiety such as a fluorescent moiety, colorimetric moiety and the like.
  • detectable moiety such as a fluorescent moiety, colorimetric moiety and the like.
  • One of skill in the art can consult references directed to labeling nucleic acids.
  • fluorescent moieties include, but are not limited to, yellow fluorescent protein (YFP), green fluorescent protein (GFP), cyan fluorescent protein (CFP), red fluorescent protein (RFP), umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, cyanines, dansyl chloride, phycocyanin, phycoerythrin and the like.
  • YFP yellow fluorescent protein
  • GFP green fluorescent protein
  • CFP cyan fluorescent protein
  • RFP red fluorescent protein
  • umbelliferone fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, cyanines, dansyl chloride, phycocyanin, phycoerythrin and the like.
  • One or more fluorescent dyes can be used as labels for labeled target sequences, e.g., as disclosed by U.S. Patent Nos. 5,188,934 (4,7-dichlorofluorescein dyes); 5,366,860 (spectrally resolvable rhodamine dyes); 5,847,162 (4,7-dichlororhodamine dyes); 4,318,846 (ether-substituted fluorescein dyes); 5,800,996 (energy transfer dyes); Lee etal. 5,066,580 (xanthine dyes); 5,688,648 (energy transfer dyes); and the like. Labelling can also be carried out with quantum dots, as disclosed in the following patents and patent publications: U.S. Patent Nos. 6,322,901; 6,576,291; 6,423,551; 6,251,303; 6,319,426; 6,426,513; 6,444,143; 5,990,479; 6,207,392;
  • fluorescent label comprises a signaling moiety that conveys information through the fluorescent absorption and/or emission properties of one or more molecules.
  • fluorescent properties include fluorescence intensity, fluorescence lifetime, emission spectrum characteristics, energy transfer, and the like.
  • fluorescent nucleotide analogues readily incorporated into nucleotide and/or oligonucleotide sequences include, but are not limited to, Cy3-dCTP, Cy3- dUTP, Cy5-dCTP, Cy5-dUTP (Amersham Biosciences, Piscataway, NJ), fluorescein- 12- dUTP, tetramethylrhodamine-6-dUTP, TEXAS REDTM-5-dUTP, CASCADE BLUETM-7- dUTP, BODIPY TMFL-14-dUTP, BODIPY TMR-14-dUTP, BODIPY TMTR-14-dUTP, RHOD AMINE GREENTM-5-dUTP, OREGON GREENRTM 488-5-dUTP, TEXAS REDTM- 12-dUTP, BODIPY TM 630/650- 14-dUTP, BODIPY TM 650/665- 14
  • fluorophores and those mentioned herein can be added during oligonucleotide synthesis using for example phosphoroamidite or NHS chemistry. Protocols are known in the art for custom synthesis of nucleotides having other fluorophores (See, Henegariu et al. (2000) Nature Biotechnol. 18:345).
  • 2-Aminopurine is a fluorescent base that can be incorporated directly in the oligonucleotide sequence during its synthesis. Nucleic acid could also be stained, a priori, with an intercalating dye such as DAPI, YOYO- 1 , ethidium bromide, cyanine dyes (e.g., SYBR Green) and the like.
  • fluorophores available for post-synthetic attachment include, but are not limited to, ALEXA FLUORTM 350, ALEXA FLUORTM 405, ALEXA FLUORTM 430, ALEXA FLUORTM 532, ALEXA FLUORTM 546, ALEXA FLUORTM 568, ALEXA
  • FLUORTM 594 ALEXA FLUORTM 647, BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, Pacific Orange, rhodamine 6G, rhodamine green, rhodamine red, tetramethyl rhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7 (Amersham Biosciences, Piscataway, NJ)
  • FRET tandem fluorophores can also be used, including, but not limited to, PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, APC-Cy7, PE-Alexa dyes (610, 647, and 680), APC-Alexa dyes and the like.
  • Metallic silver or gold particles can be used to enhance signal from fluorescently labeled nucleotide and/or oligonucleotide sequences (Lakowicz elal. (2003) BioTechniques 34:62).
  • Suitable labels for an oligonucleotide sequence can include fluorescein (FAM, FITC), digoxigenin, dinitrophenol (DNP), dansyl, biotin, bromodeoxyuridine (BrdU), hexahistidine (6xHis), phosphor-amino acids (e.g., P-tyr, P-ser, P-thr) and the like.
  • hapten/antibody pairs can be used for detection, in which each of the antibodies is derivatized with a detectable label: biotin/a-biotin, digoxigenin/a-digoxigenin, dinitrophenol (DNPya-DNP, 5-Carboxyfluorescein (FAM)/a-FAM.
  • Figure 1 shows an illustrative schematic of an exemplary nanoreporter probe comprising a target binding domain and a barcode domain in which the interface between the target binding domain and the barcode domain comprises the photocleavable linker of the present disclosure.
  • FIG. 2 shows an exemplary nanoreporter probe complex comprising the photocleavable linker of the present disclosure.
  • the nanoreporter probe complex comprises seven nanoreporter probes.
  • One nanoreporter probe in this example referred to as the primary nanoreporter probe, comprises a target binding domain and a barcode domain, in which the interface between the target binding domain and the barcode domain comprises the photocleavable linker of the present disclosure.
  • Six nanoreporter probes, in this example referred to as secondary nanoreporter probes are hybridized to the barcode domain of the primary nanoreporter. Each secondary nanoreporter probe is hybridized to 5 molecules that are bound to a detectable label.
  • the positioning of the cleavable linker of the present disclosure allows for the controllable and rapid separation of the target binding and barcode domains of the primary nanoreporter probe.
  • This controllable and rapid separation can be beneficial in various applications, including the detection and sequencing of target nucleic acids, as it allows a user to remove the detectable signal from specific nanoreporter probe to allow for easier detection of other nanoreporter probes.
  • FIG. 3 is a schematic illustration of an exemplary sequencing method using a nanoreporter probe comprising the cleavable linker modification of the present disclosure.
  • a nanoreporter probe referred to in this example as a sequencing probe
  • a secondary nanoreporter probe is hybridized to a position on the barcode domain of the sequencing probe. This position of the barcode domain of the sequencing probe corresponds to the identity of the first two nucleotides of the target binding domain of the sequencing probe.
  • the secondary nanoreporter probe that hybridizes to this position also corresponds to the identity of these first two nucleotides.
  • the barcode domain of the secondary nanoreporter probe is hybridized to oligos labeled with fluorescent dyes.
  • the secondary nanoreporter probe comprises a sequence such that three oligos that are labeled with a green dye and three oligos that are labeled with a red dye are hybridized, creating a green-red color combination that corresponds to the identity of the first two nucleotides of the target binding domain.
  • the user can identify the first two nucleotides of the target binding domain of the sequencing probes and thereby, the identity of the complementary nucleotides in the target nucleic acid.
  • the linker of the present disclosure is cleaved using UV light to separate the labeled barcode domain and target binding domain of the secondary nanoreporter probe, thereby ensuring that the sequencing probe no longer emits a detectable signal associated with the identity of the first two nucleotides of the target binding domain.
  • a different secondary nanoreporter probe is hybridized to a position of the barcode domain of the sequencing probe. This position corresponds to the identity of the third and fourth nucleotides of the target binding domain of the sequencing probe.
  • the secondary nanoreporter probe that hybridizes in this position is therefore specific to the identity of the third and fourth nucleotides of the target binding domain.
  • the barcode domain of this secondary nanoreporter probe is hybridized to labeled oligos such that the secondary nanoreporter probe emits a detectable signal that is specific to the identity of the third and fourth nucleotides of the target binding domain.
  • the photocleavable linker of the present disclosure is necessary to remove the labeled barcode domain that corresponds to the identity of the first two nucleotides to allow for the detection of the labeled barcode domain that corresponds to the identity of the third and fourth nucleotides. If the labeled barcode domain that corresponds to the identity of the first two nucleotides was not removed, the fluorescent signals from the barcode domains of the two secondary nanoreporter probes would not be distinguishable using standard fluorescence microscopy techniques.
  • Figure 4 shows an exemplary nanoreporter probe complex and the locations within the complex that could comprise the photocleavable linker of the present disclosure. The structure of the nanoreporter complex is the same as that depicted in Figure 2.
  • the reporter probe may comprise two label attachment regions, wherein the first and second label attachment regions are capable of hybridizing to a first and second DNA or RNA molecule respectively, and each first and second DNA or RNA molecule is attached to one or more label monomers that emit light that constitute a first and second signal, respectively.
  • the second probe may comprise three or more label attachment regions, wherein at each label attachment region, an DNA or RNA molecule attached to one or more label monomers that emit light that constitute a signal can bind. The signals emitted from the labeled monomers contribute to the code that identifies the specific target molecule.
  • the present disclosure also provides a method of preparing probes that include a linker of the present disclosure.
  • the method comprises: 1) Dissolving 32.7 nmol of 3'-amino modified 84mer oligo, with the nucleotide sequence
  • the method further comprising: 7) After approximately 18 hours of reaction, quenching the excess NHS-ester in the solution of step 6 by reacting the NHS-ester with a 1.1 molar excess of Tris-HCl (2.04 uL of 1 M Tris-HCl solution) for 15 minutes at RT; 8) To the resulting reaction mixture, adding 3 M NaOAc (10.7 ⁇ L to render 10% by volume), followed by 321.6 ⁇ , of ice cold EtOH to precipitate desired DNA-conjugate intermediate; 9) Vortexing the suspension for about 10 seconds, spining briefly via benchtop centrifuge, and incubating in -80°C freezer for 1 hour; 10) Centrifuging the desired intermediate product at 4°C for 30 minutes at full speed (13,500 RPM), and washing the resulting pellet twice with 200 ⁇ L of ice cold 70% aq. EtOH. After each wash and prior to decanting or pipette removal of supernatants, spinning briefly via benchtop centrifuge at 4°C for 10 minutes at
  • the method further comprising: 12) Dissolving 195.9 nmol of reporter molecule (5'- ThioMC6-D/CGAGAATCCTAGAC, SEQ ID NO: 2) in 195.9 ⁇ L ⁇ of PBS pH 7.4, resulting in a reporter molecule concentration of 1.0 mM concentration; 13) To the 1.0 mM reporter solution, adding a 100-fold excess of TCEP reagent (19.6 umol; 39.2 ⁇ L of 0.5 M solution of TCEP) to reduce any disulfide linkages to free thiol groups.
  • This reaction corresponds to a 6-fold excess of the reduced 14mer thiol relative to the maleimide reactive group of the 84mer conjugate; 18) Vortexing the combined mixture for 10 seconds to mix, briefly spinning down, and allowing to react at RT for at least 2 hours in the dark (or overnight); 19) Purifying the resulting product via RP-HPLC under standard nucleic acid purification conditions to afford final desired bifunctional 98mer product.
  • the reporter probes of the present disclosure can be labeled with any of a variety of label monomers, such as a fluorochrome, dye, enzyme, nanoparticle, chemiluminescent marker, biotin, or other monomer known in the art that can be detected directly (e.g., by light emission) or indirectly (e.g., by binding of a fluorescently-labeled antibody).
  • label monomers such as a fluorochrome, dye, enzyme, nanoparticle, chemiluminescent marker, biotin, or other monomer known in the art that can be detected directly (e.g., by light emission) or indirectly (e.g., by binding of a fluorescently-labeled antibody).
  • one or more of the label attachments regions in the reporter probe is labeled with one or more label monomers, and the signals emitted by the label monomers attached to the label attachment regions of a reporter probe or capture probe constitute a code that identifies the target.
  • the lack of a given signal from the label attachment region i
  • the present disclosure also provides a probe pair which includes a reporter probe as described herein and a capture probe.
  • a capture probe comprises a first region containing a target-specific sequence, and a second non-overlapping region containing one or more affinity moieties.
  • the reporter probe and capture probe bind to the same target molecule at non-overlapping locations.
  • the affinity moieties can be utilized for purification and/or for immobilization.
  • the affinity moieties may be attached to the capture probe by covalent or non-covalent means.
  • Various affinity moieties appropriate for purification and/or for immobilization are known in the art.
  • the affinity moiety is biotin.
  • the capture probe may contain a second affinity moiety, such as repeat sequences, which are used for affinity purification through hybridization to an oligonucleotide column, in which the column contains oligonucleotides that are
  • the capture probe comprises at least one label attachment region that is hybridized to at least one RNA or DNA molecule, wherein the RNA or DNA molecule is labeled or attached to one or more label monomers that emit a signal that contributes to the code.
  • the present disclosure also provides methods of detecting or quantifying an individual or plurality of target molecules in a biomolecular sample, using the compositions described herein.
  • the methods of detection are performed in multiplex assays, whereby a plurality of target molecules are detected in the same assay (a single reaction mixture).
  • the assay is a hybridization assay in which the plurality of target molecules are detected simultaneously.
  • the plurality of target molecules detected in the same assay is at least 5 different target molecules, at least 10 different target molecules, at least 20 different target molecules, at least SO different target molecules, at least 75 different target molecules, at least 100 different target molecules, at least 200 different target molecules, at least 500 different target molecules, or at least 750 different target molecules, or at least 1000 different target molecules.
  • the plurality of target molecules detected in the same assay is up to 50 different target molecules, up to 100 different target molecules, up to 150 different target molecules, up to 200 different target molecules, up to 300 different target molecules, up to 500 different target molecules, up to 750 different target molecules, up to 1000 different target molecules, up to 2000 different target molecules, or up to 5000 different target molecules.
  • the plurality of target molecules detected is any range in between the foregoing numbers of different target molecules, such as, but not limited to, from 20 to 50 different target molecules, from 50 to 200 different target molecules, from 100 to 1000 different target molecules, from 500 to 5000 different target molecules, and so on and so forth.
  • the target molecule is DNA (including cDNA) or RNA (including mRNA and cRNA).
  • the present disclosure may be particularly useful for multiplex assays to detect a plurality of target molecules in a sample, for example, a set of genes.
  • Each target molecule, or gene of interest, in a multiplex assay is associated with a unique reporter code as designated by the unique linear arrangement of label monomers associated with the reporter probe.
  • Nanoreporters can bind to target molecules directly or indirectly via an
  • Nanoreporter systems that utilize capture and reporter probes that contain target-specific sequences for binding directly to the target molecule are described in U.S. Patent Publications US2010/0015607 and US2010/0047924. Nanoreporter systems that indirectly bind to the target molecule are described in U.S. Patent Publication US2014/0371088.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé ortho-nitrobenzyle, ou un stéréoisomère ou un sel de celui-ci, et une composition le comprenant, ainsi que des procédés de préparation de ceux-ci. L'invention concerne également un procédé d'utilisation du composé ortho-nitrobenzyle, ou d'un stéréoisomère de celui-ci, dans des sondes capables de s'hybrider à, de détecter ou de séquencer des molécules d'acide nucléique.
PCT/US2018/062072 2017-11-21 2018-11-20 Lieur bifonctionnel photoclivable o-nitrobenzyle Ceased WO2019104070A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589067P 2017-11-21 2017-11-21
US62/589,067 2017-11-21

Publications (1)

Publication Number Publication Date
WO2019104070A1 true WO2019104070A1 (fr) 2019-05-31

Family

ID=64661499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/062072 Ceased WO2019104070A1 (fr) 2017-11-21 2018-11-20 Lieur bifonctionnel photoclivable o-nitrobenzyle

Country Status (1)

Country Link
WO (1) WO2019104070A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US5066580A (en) 1988-08-31 1991-11-19 Becton Dickinson And Company Xanthene dyes that emit to the red of fluorescein
US5091519A (en) 1986-05-01 1992-02-25 Amoco Corporation Nucleotide compositions with linking groups
US5151507A (en) 1986-07-02 1992-09-29 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US5188934A (en) 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5688648A (en) 1994-02-01 1997-11-18 The Regents Of The University Of California Probes labelled with energy transfer coupled dyes
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5847162A (en) 1996-06-27 1998-12-08 The Perkin Elmer Corporation 4, 7-Dichlororhodamine dyes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
WO1999067619A2 (fr) * 1998-06-02 1999-12-29 Ambergen, Inc. Composes et procedes pour la detection de biomolecules
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US20020045045A1 (en) 2000-10-13 2002-04-18 Adams Edward William Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6426513B1 (en) 1998-09-18 2002-07-30 Massachusetts Institute Of Technology Water-soluble thiol-capped nanocrystals
US20030017264A1 (en) 2001-07-20 2003-01-23 Treadway Joseph A. Luminescent nanoparticles and methods for their preparation
US6576291B2 (en) 2000-12-08 2003-06-10 Massachusetts Institute Of Technology Preparation of nanocrystallites
US20080227742A1 (en) * 2006-11-27 2008-09-18 Ivan Dmochowski Photocleavable oligonucleotide and uses thereof
US20100015607A1 (en) 2005-12-23 2010-01-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
US20100047924A1 (en) 2008-08-14 2010-02-25 Nanostring Technologies, Inc. Stable nanoreporters
US20140371088A1 (en) 2013-06-14 2014-12-18 Nanostring Technologies, Inc. Multiplexable tag-based reporter system

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US5091519A (en) 1986-05-01 1992-02-25 Amoco Corporation Nucleotide compositions with linking groups
US5151507A (en) 1986-07-02 1992-09-29 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US5066580A (en) 1988-08-31 1991-11-19 Becton Dickinson And Company Xanthene dyes that emit to the red of fluorescein
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5188934A (en) 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
US5688648A (en) 1994-02-01 1997-11-18 The Regents Of The University Of California Probes labelled with energy transfer coupled dyes
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5847162A (en) 1996-06-27 1998-12-08 The Perkin Elmer Corporation 4, 7-Dichlororhodamine dyes
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6423551B1 (en) 1997-11-25 2002-07-23 The Regents Of The University Of California Organo luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
WO1999067619A2 (fr) * 1998-06-02 1999-12-29 Ambergen, Inc. Composes et procedes pour la detection de biomolecules
US6426513B1 (en) 1998-09-18 2002-07-30 Massachusetts Institute Of Technology Water-soluble thiol-capped nanocrystals
US6319426B1 (en) 1998-09-18 2001-11-20 Massachusetts Institute Of Technology Water-soluble fluorescent semiconductor nanocrystals
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6444143B2 (en) 1998-09-18 2002-09-03 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US20020045045A1 (en) 2000-10-13 2002-04-18 Adams Edward William Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6576291B2 (en) 2000-12-08 2003-06-10 Massachusetts Institute Of Technology Preparation of nanocrystallites
US20030017264A1 (en) 2001-07-20 2003-01-23 Treadway Joseph A. Luminescent nanoparticles and methods for their preparation
US20100015607A1 (en) 2005-12-23 2010-01-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
US20080227742A1 (en) * 2006-11-27 2008-09-18 Ivan Dmochowski Photocleavable oligonucleotide and uses thereof
US20100047924A1 (en) 2008-08-14 2010-02-25 Nanostring Technologies, Inc. Stable nanoreporters
US20140371088A1 (en) 2013-06-14 2014-12-18 Nanostring Technologies, Inc. Multiplexable tag-based reporter system

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Oligonucleotides and Analogues: A Practical Approach", 1991, IRL PRESS
ELIEL, E.; WILEN, S.: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS, INC.
HASAN ET AL., TETRAHEDRON, vol. 53, 1997, pages 4247 - 4264
HAUGLAND: "Handbook of Fluorescent Probes and Research Chemicals", 2002, MOLECULAR PROBES, INC.
HENEGARIU ET AL., NATURE BIOTECHNOL., vol. 18, 2000, pages 345
KELLER; MANAK: "DNA Probes", 1993, STOCKTON PRESS
LAKOWICZ, BIOTECHNIQUES, vol. 34, 2003, pages 62
LOCHMULLER, C. H. ET AL.: "Chromatographic resolution of enantiomers: Selective review.", J. CHROMATOGR., vol. 113, no. 3, 1975, pages 283 - 3
OLEJNIK ET AL., NUCLEIC ACIDS RES., vol. 26, 1998, pages 3572 - 3576
OLEJNIK ET AL., NUCLEIC ACIDS RES., vol. 27, 1999, pages 4626 - 4631
OLEJNIK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 7590 - 7594
PEASE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 5022 - 5026
WAINER; IRVING W.: "Ed Drug Stereochemistry: Analytical Methods and Pharmacology", 1993, MARCEL DEKKER, INC.
WETMUR, CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 26, 1991, pages 227 - 259

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US11452711B2 (en) 2020-09-03 2022-09-27 Pfizer Inc. Nitrile-containing antiviral compounds
US11541034B2 (en) 2020-09-03 2023-01-03 Pfizer Inc. Nitrile-containing antiviral compounds

Similar Documents

Publication Publication Date Title
AU2019271121B2 (en) Compositions and methods for chemical cleavage and deprotection of surface-bound oligonucleotides
EP3559004B1 (fr) Composés coumarines et leurs utilisations en tant que marqueurs fluorescents
JP5646172B2 (ja) リポーター分子の製造のためのクリックケミストリー
ES2380923T3 (es) Procedimientos de cuantificación de microARN y ARN interferentes pequeños
JP4713514B2 (ja) 改善された標識試薬
US8133984B2 (en) Oligonucleotides comprising signalling pairs and hydrophobic nucleotides, stemless beacons, for detection of nucleic acids, methylation status and mutants of nucleic acids
JP2003505109A (ja) 核酸の捕獲及び検出の為の、シッフ塩基型結合による固体担体へのオリゴヌクレオチドの付着
CN102124018A (zh) 可维持从核苷酸模板酶促合成双链核苷酸的非天然聚合酶底物及其使用的方法
KR20020007332A (ko) 일 단계 샘플 제조 및 복합적인 생물학적 샘플에서 핵산의검출
JPH04507402A (ja) 架橋オリゴヌクレオチド
WO1987001373A1 (fr) Derives de nucleotides de pyridopyrimidine
JP2009149605A (ja) ６員環を有するヌクレオチドアナログ
CN119604513A (zh) 含有稠合四环双硼杂环的荧光染料及其在测序中的用途
JPWO2005026187A1 (ja) 非天然型塩基を有するヌクレオシド又はヌクレオチド及びその利用
US6664058B2 (en) Base analogues
JP2001502665A (ja) 複素環式化合物および核酸検出におけるその使用
JP2023546741A (ja) 修飾ヌクレオシド又はヌクレオチド
JP3753942B2 (ja) ５−ピリミジン含有核酸、それを用いた可逆的連結方法
WO2019104070A1 (fr) Lieur bifonctionnel photoclivable o-nitrobenzyle
JP2001526639A (ja) 三環式塩基類似体
CN116322706B (zh) 新人工核酸、其制造方法和用途
EP4588924A1 (fr) Composés phosphoramidites et procédés de préparation d'acides nucléiques synthétiques
WO2024240051A1 (fr) Colorant fluorescent, sa synthèse et son utilisation
JP2014512175A (ja) 積層核酸及びそれを使用するための方法
JP2007224013A (ja) 非天然塩基

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18815895

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18815895

Country of ref document: EP

Kind code of ref document: A1